Home » Stocks » ARGX

Argenx SE (ARGX)

Stock Price: $277.25 USD -4.47 (-1.59%)
Updated Apr 19, 2021 11:06 AM EDT - Market open
Market Cap 14.21B
Revenue (ttm) 44.42M
Net Income (ttm) -645.03M
Shares Out 50.70M
EPS (ttm) -13.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $277.25
Previous Close $281.72
Change ($) -4.47
Change (%) -1.59%
Day's Open 279.28
Day's Range 277.02 - 281.93
Day's Volume 43,525
52-Week Range 141.26 - 382.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

Other stocks mentioned: BHVN, BMRN, MRTX, NVO, NVS
1 month ago - InvestorPlace

Shares of argenx (NASDAQ:ARGX) fell 3.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 60.08% year over year to ($4.21), which missed the es...

1 month ago - Benzinga

- Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG)

1 month ago - GlobeNewsWire

The FDA has accepted for review Argenx SE's (NASDAQ: ARGX) marketing application seeking approval for intravenous (IV) efgartigimod, for the treatment of generalized myasthenia gravis (gMG). Myasthenia ...

1 month ago - Benzinga

February 25, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, ...

1 month ago - GlobeNewsWire

Regulated information

2 months ago - GlobeNewsWire

Regulated information — Inside information

2 months ago - GlobeNewsWire

Regulated information — Inside information

2 months ago - GlobeNewsWire

-No observed elevation of cholesterol markers related to treatment with efgartigimod

2 months ago - GlobeNewsWire

Regulated information — Inside information

2 months ago - GlobeNewsWire

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...

Other stocks mentioned: EYPT, GILD, GRCL, INO, LLY, PRTK, ZLAB
3 months ago - Seeking Alpha

Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, to...

3 months ago - GlobeNewsWire

January 4, 2021 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseas...

3 months ago - GlobeNewsWire

November 23, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune dise...

4 months ago - GlobeNewsWire

BREDA, the Netherlands and GHENT, Belgium, Nov. 17, 2020 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe au...

5 months ago - PRNewsWire

November 9, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disea...

5 months ago - GlobeNewsWire

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Shares of argenx (NASDAQ:ARGX) decreased 6.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 450.00% year over year to ($3.96), which missed ...

5 months ago - Benzinga

- Biologics License Application (BLA) for efgartigimod in generalized myasthenia gravis (gMG) on track to be submitted to U.S. Food and Drug Administration (FDA) by end of 2020 -

5 months ago - GlobeNewsWire

October 15, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disea...

6 months ago - GlobeNewsWire

Argenx: Competitive Positioning In The GMG Space

6 months ago - Seeking Alpha

September 2, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune d...

7 months ago - GlobeNewsWire

August 4, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune dise...

8 months ago - GlobeNewsWire

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

July 30, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disea...

8 months ago - GlobeNewsWire

On Thursday, July 30, argenx (NASDAQ: ARGX) will release its latest earnings report.

8 months ago - Benzinga

argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

9 months ago - Zacks Investment Research

Regulated information

10 months ago - GlobeNewsWire

Regulated information — Inside information

10 months ago - GlobeNewsWire

Regulated information — Inside information

10 months ago - GlobeNewsWire

argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.

10 months ago - Zacks Investment Research

Regulated information — Inside information

10 months ago - GlobeNewsWire

Positive pivotal trial results are giving investors a reason to cheer.

10 months ago - The Motley Fool

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

            - Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics License Application filing by end of year -             -...

11 months ago - GlobeNewsWire

Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.

Other stocks mentioned: ASND, AXSM, FOLD, IOVA, NTRA, UTHR
11 months ago - InvestorPlace

Market Fairly Evaluates Argenx's Efgartigimod (ARGX-113) In Myasthenia Gravis

1 year ago - Seeking Alpha

Argenx: The Upside Is Still There

1 year ago - Seeking Alpha

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Top Ranked Momentum Stocks to Buy for February 27th

Other stocks mentioned: ADNT, DDOG, KNSL
1 year ago - Zacks Investment Research

argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 year ago - Zacks Investment Research

The American Society of Hematology (ASH) hosted its 61st annual meeting, and one of the biggest biotech events, earlier this week in Orlando, Florida.

Other stocks mentioned: BLUE, BPMC, EPZM, FATE, MGTA
1 year ago - 24/7 Wall Street

Regulated information – Inside information

1 year ago - GlobeNewsWire

Regulated information – Inside information

1 year ago - GlobeNewsWire

About ARGX

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indic... [Read more...]

Industry
Biotechnology
IPO Date
May 18, 2017
CEO
Tim Van Hauwermeiren
Employees
336
Stock Exchange
NASDAQ
Ticker Symbol
ARGX
Full Company Profile

Financial Performance

In 2020, Argenx SE's revenue was 36.43 million, a decrease of -47.80% compared to the previous year's 69.78 million. Losses were -528.92 million, 224.6% more than in 2019.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 17 analysts, the average rating for Argenx SE stock is "Buy." The 12-month stock price forecast is 338.31, which is an increase of 22.02% from the latest price.

Price Target
$338.31
(22.02% upside)
Analyst Consensus: Buy